GE and DARPA are collaborating on a $2.9 million study of neuromodulation as a treatment for Type 2 diabetes.
GE scientists have developed a novel, potentially breakthrough approach that could restore nerve signals to a healthy state using non-invasive devices that stimulate metabolic biosystems and produce drug-like effects, but with greater precision than traditional treatments, and with fewer side effects.
Get the full story on our sister site, Medical Design & Outsourcing.
